On April 13, 2021 BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center reported a collaboration to translate research in genetically driven diseases and cancers into potential treatments for patients (Press release, BridgeBio, APR 13, 2021, View Source [SID1234578029]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The Lundquist Institute is renowned for its scientific research and drug discoveries, and we look forward to developing a close relationship with their talented scientists in the hope of translating their discoveries into medicines with meaningful benefit for patients," said BridgeBio CEO and Founder Neil Kumar, Ph.D.

Under the established two-year partnership, BridgeBio will work closely with The Lundquist Institute researchers to identify programs that may have the potential to become therapies for patients with genetically driven conditions and cancers. BridgeBio will potentially sponsor research programs and support the development of Lundquist programs and clinical investigations through its licensing and affiliate development model.

"By coupling our world-class scientific discoveries with the resources and well-seasoned team at BridgeBio, we have the opportunity to create advancements in therapeutics for genetic diseases," said Rubayath Mohsen, M.S., Manager of Business Development and Technology Transfer from The Lundquist Institute. "Based on their track record in working closely with researchers, we are optimistic about developing our technologies with BridgeBio and look forward to seeing what we can do together to develop new therapeutics for patients in need."

BridgeBio partners with top academic and research institutions throughout the U.S., including The Lundquist Institute, to support early, promising research in genetically driven diseases and cancers with clear genetic drivers. Today BridgeBio also announced formal partnerships with Brown University, GlycoNet, Oregon Health & Science University, Roswell Park Comprehensive Cancer Center, University of California, Davis and University of California, San Diego – for a total of 20 partnerships between BridgeBio and leading academic and research institutions to date. For a list of some of the institutions BridgeBio is partnered with, please visit Our Partners page.

With trust, respect and science at the forefront of all collaborations, BridgeBio will continue developing similar long-term partnerships to support its mission of pioneering critical medicines for patients with certain cancers and genetically driven conditions as quickly and safely as possible.

On April 13, 2021 Herantis Pharma Plc ("Herantis"), focusing on disease modifying therapies for debilitating neurodegenerative diseases, reported that Dr. Craig Cook, Chief Executive Officer, will hold 1×1 meetings and have a digital company presentation in the upcoming Nordic Life Science Days conference (Press release, Herantis Pharma, APR 13, 2021, View Source,c3324050 [SID1234577949]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event Details:

Nordic Life Science Days Digital

Dates: 20 – 23 April 2021

On 20 April 2021 all presentations will be available via a digital library, which is accessible to event participants only. Please contact the organizers at the Nordic Life Science Days if you wish to attend.

On April 13, 2021 BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) reported a partnership to translate research in genetically driven conditions into potential therapeutic applications for patients, with a focus on oncology and neurology (Press release, BridgeBio, APR 13, 2021, View Source [SID1234577970]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"UC San Diego is a leading research institution with a top pharmacology department and a strong profile in neurology and oncology. By leveraging their expertise through our collaboration partnership, we hope to advance discoveries into potential treatments as quickly and safely as possible," said BridgeBio founder and CEO Neil Kumar, Ph.D.

Under this partnership, BridgeBio and UC San Diego will collaborate on identifying research programs with strong potential for therapeutic applications that address areas of unmet need. BridgeBio will potentially sponsor research programs and support the development of identified programs toward potential clinical investigation through its licensing and affiliate development model.

"Our world-renown scientists have deep knowledge into genetically driven conditions. Coupling our cross-disciplinary, flexible approach to advancing research with BridgeBio’s developmental expertise and collaborative model presents tremendous opportunity to realize the potential of our work," said UC San Diego Associate Vice Chancellor for Innovation and Commercialization Paul Roben. "I look forward to seeing our collaboration advance around our shared mission to develop life-changing therapies and give patients new hope."

BridgeBio partners with top academic and research institutions, including UC San Diego, to support early, promising research in genetically driven diseases and cancers with clear genetic drivers. Today BridgeBio also announced formal partnerships with Brown University, GlycoNet, The Lundquist Institute, Oregon Health & Science University, Roswell Park Comprehensive Cancer Center and University of California, Davis – for a total of 20 partnerships between BridgeBio and leading academic and research institutions to date. For a list of some of the institutions BridgeBio is partnered with, please visit Our Partners page.

With trust, respect and science at the forefront of all collaborations, BridgeBio continuously seeks long-term partnerships with similar institutions that are rooted in trust, engagement, science and respect in order to drive forward its mission of developing life-changing medicines for patients with genetically driven conditions, including in oncology and neurology, as quickly and safely as possible.

On April 13, 2021 Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, reported that members of its senior management team will present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference on Tuesday, April 20 at 9:30 a.m. ET (Press release, Repare Therapeutics, APR 13, 2021, View Source [SID1234577987]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed in the Investor section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 30 days.

On April 13, 2021 Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, reported that its abstract entitled, "Vaccination with Polyclonal Antibody Stimulator (PAS) prevents pancreatic carcinogenesis in the KRAS mouse model" has been selected for presentation in a minisymposium at the AACR (Free AACR Whitepaper) Annual Meeting 2021 (Press release, Cancer Advances, APR 13, 2021, View Source [SID1234577972]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jill Smith, MD of the Georgetown Lombardi Comprehensive Cancer Center, will present the results of this study during the week of April 10-15, 2021. The pre-recorded presentation will be available for viewing during the meeting. A live Q&A session will be held April 12, 1:30 pm EDT. In addition, attendees have the opportunity to contact Dr. Smith via a networking portal to discuss the research further.

Details of the abstract and minisymposium are below:

Abstract Title: Vaccination with Polyclonal Antibody Stimulator (PAS) prevents pancreatic carcinogenesis in the KRAS mouse model

Abstract Number: 109

Q&A Session: April 12, 1:30 pm EDT

Abstract/Session Link: View Source!/9325/presentation/1168